Evidence map›Paper›PMID 39008191›Full record

ReviewJournal of patient-reported outcomes2024

Capturing patient-reported sleep disturbance in atopic dermatitis clinical trials.

Carla Dias-Barbosa, Jonathan I Silverberg, Sonja Ständer, Danielle Rodriguez, Fatoumata Fofana, Dina Filipenko, Liliana Ulianov, Christophe Piketty, Jorge Puelles

3 registry-linked trialsAbstract readReview
In one paragraph

Review in Journal of patient-reported outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03100344 phase2completednot on this map

Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving Topical Corticosteroids (TCS)

TypeinterventionalSponsorGalderma R&DRan2017 to 2018Enrolled226ConditionsAtopic DermatitisArmsNemolizumab, Placebo
NCT03985943 phase3completednot on this map

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

TypeinterventionalSponsorGalderma R&DRan2019 to 2022Enrolled941ConditionsModerate-to-Severe Atopic DermatitisArmsPlacebo, Nemolizumab
NCT03989349 phase3completednot on this map

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

TypeinterventionalSponsorGalderma R&DRan2019 to 2022Enrolled787ConditionsModerate-to-Severe Atopic DermatitisArmsPlacebo, Nemolizumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carla Dias-BarbosaEvidera, Ivry-sur-Seine, France. carla.dias-barbosa@evidera.com.
Jonathan I SilverbergGeorge Washington University School of Medicine and Health Sciences, Washington, D.C., USA.
Sonja StänderDepartment of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.
Danielle RodriguezEvidera, Seattle, WA, USA.
Fatoumata FofanaEvidera, Bennekom, The Netherlands.
Dina FilipenkoEvidera, London, UK.
Liliana UlianovGalderma, Zug, Switzerland.
Christophe PikettyGalderma, Zug, Switzerland.
Jorge PuellesGalderma, Zug, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatient-focused approaches to capturing day-to-day variability in sleep disturbance are needed to properly evaluate the sleep benefits of new treatments. Such approaches rely on patient-reported outcome (PRO) measures validated in the target patient population.

methodsUsing atopic dermatitis (AD) as an example of a disease in which sleep is commonly disturbed, we developed a strategy for measuring sleep disturbance in AD trials. In developing this strategy, we conducted a targeted literature review and held concept elicitation interviews with adolescents and adults with AD. We subsequently identified potentially suitable PRO measures and cognitively debriefed them. Finally, we evaluated their psychometric properties using data from phase 2b (NCT03100344) and phase 3 (NCT03985943 and NCT03989349) clinical trials.

resultsThe literature review confirmed that sleep disturbance is a key impact of AD but failed to identify validated PRO measures for assessing fluctuations in sleep disturbance. Subsequent concept elicitation interviews confirmed the multidimensional nature of sleep disturbance in AD and supported use of a single-item measure to assess overall sleep disturbance severity, complemented by a diary to capture individual components of sleep disturbance. The single-item sleep disturbance numerical rating scale (SD NRS) and multi-item Subject Sleep Diary (SSD)-an AD-adapted version of the Consensus Sleep Diary-were identified as potentially suitable PRO measures. Cognitive debriefing of the SD NRS and SSD demonstrated their content validity and their understandability to patients. Psychometric analyses based on AD trial data showed that the SD NRS is a well-defined, reliable, and fit-for-purpose measure of sleep disturbance in adults with AD. Furthermore, the SD NRS correlated with many SSD sleep parameters, suggesting that most concepts from the SSD can be covered using the SD NRS.

conclusionsUsing these findings, we developed an approach for measuring sleep disturbance in AD trials. Subject to further research, the same approach could also be applied to future trials of other skin diseases where itch causes sleep disturbance.

Indexed as

Dermatitis, AtopicPatient Reported Outcome MeasuresSleep Wake DisordersAdolescentAdultClinical Trials as TopicFemaleHumansMaleMiddle AgedPsychometricsSeverity of Illness IndexYoung AdultAtopicContent validityDermatitisPatient reported outcome measuresPsychometricsSleep Wake disorders

Identifiers

PMID39008191
PMCPMC11250737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.